Clinical Trial Update: A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating Disitamab Vedotin, Tunlametinib, and a PD-1 antibody for advanced gastric adenocarcinoma; the study is not yet recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• PD-1 antibody (PD-1 inhibitor)
• Tunlametinib (tunlametinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Gastric Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING